cardiology
DOAC Score for Selecting Direct Oral Anticoagulant in Non-Valvular AF
Information page: choosing and dosing a direct oral anticoagulant in non-valvular atrial fibrillation.
Used in: Atrial Fibrillation
References
- Yao X et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5(6):e003725.
- NICE NG196. Atrial fibrillation: diagnosis and management. NICE. 2021.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Apixaban · Direct Oral Anticoagulant (DOAC) — Factor Xa Inhibitor
- Rivaroxaban · Direct oral anticoagulant (DOAC) — Factor Xa inhibitor
- Apixaban · Direct oral anticoagulant (DOAC) — Factor Xa inhibitor
- Dabigatran (AF / VTE) · Direct Oral Anticoagulant / AF
- Edoxaban (AF / VTE) · Direct Oral Anticoagulant / AF
- Rivaroxaban (AF / ACS) · Direct Oral Anticoagulant / AF / ACS
Pathways
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Featured in these MRCEM clinical pathways
The DOAC Score is covered in detail — with RCEM/NICE evidence base, indications and pitfalls — in the following exam-focused pathways on our sister siteReviseMRCEM.
MRCEM Primary / Intermediate / OSCE candidates: each pathway includes exam-style questions, RCEM/NICE citations, and FAQ summaries.
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.